222 related articles for article (PubMed ID: 34348766)
1. NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network.
Mammarella E; Zampieri C; Panatta E; Melino G; Amelio I
Biol Direct; 2021 Aug; 16(1):11. PubMed ID: 34348766
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations define the chromatin landscape to confer drug tolerance in pancreatic cancer.
Zampieri C; Panatta E; Corbo V; Mauriello A; Melino G; Amelio I
Mol Oncol; 2022 Mar; 16(6):1259-1271. PubMed ID: 34919788
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
4. The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3.
Vaughan CA; Singh S; Subler MA; Windle JJ; Inoue K; Fry EA; Pillappa R; Grossman SR; Windle B; Andrew Yeudall W; Deb SP; Deb S
Nat Commun; 2021 Jan; 12(1):704. PubMed ID: 33514736
[TBL] [Abstract][Full Text] [Related]
5. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
[TBL] [Abstract][Full Text] [Related]
6. A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.
Koifman G; Shetzer Y; Eizenberger S; Solomon H; Rotkopf R; Molchadsky A; Lonetto G; Goldfinger N; Rotter V
Cancer Res; 2018 Oct; 78(20):5833-5847. PubMed ID: 30154152
[TBL] [Abstract][Full Text] [Related]
7. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells.
Cordani M; Butera G; Pacchiana R; Masetto F; Mullappilly N; Riganti C; Donadelli M
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111081
[TBL] [Abstract][Full Text] [Related]
10. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
Stein Y; Rotter V; Aloni-Grinstein R
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein Y; Aloni-Grinstein R; Rotter V
Carcinogenesis; 2020 Dec; 41(12):1635-1647. PubMed ID: 33159515
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.
Ferraiuolo M; Verduci L; Blandino G; Strano S
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467351
[TBL] [Abstract][Full Text] [Related]
13. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
[TBL] [Abstract][Full Text] [Related]
14. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression.
Amelio I; Mancini M; Petrova V; Cairns RA; Vikhreva P; Nicolai S; Marini A; Antonov AA; Le Quesne J; Baena Acevedo JD; Dudek K; Sozzi G; Pastorino U; Knight RA; Mak TW; Melino G
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10869-E10878. PubMed ID: 30381462
[TBL] [Abstract][Full Text] [Related]
15. Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
Dhaka B; Sabarinathan R
BMC Cancer; 2021 Jun; 21(1):669. PubMed ID: 34090364
[TBL] [Abstract][Full Text] [Related]
16. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
17. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.
Zhu J; Sammons MA; Donahue G; Dou Z; Vedadi M; Getlik M; Barsyte-Lovejoy D; Al-awar R; Katona BW; Shilatifard A; Huang J; Hua X; Arrowsmith CH; Berger SL
Nature; 2015 Sep; 525(7568):206-11. PubMed ID: 26331536
[TBL] [Abstract][Full Text] [Related]
18. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
Nesslinger NJ; Shi XB; deVere White RW
Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
[TBL] [Abstract][Full Text] [Related]
19. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer.
Xia W; Bai H; Deng Y; Yang Y
J Cell Mol Med; 2020 Nov; 24(21):12642-12655. PubMed ID: 32985124
[TBL] [Abstract][Full Text] [Related]
20. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.
Yue X; Zhang C; Zhao Y; Liu J; Lin AW; Tan VM; Drake JM; Liu L; Boateng MN; Li J; Feng Z; Hu W
Genes Dev; 2017 Aug; 31(16):1641-1654. PubMed ID: 28947497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
